Related Experiment Video
Updated: Jul 10, 2026
07:32
Bacterial Expression and Purification of Human Matrix Metalloproteinase-3 using Affinity Chromatography
Published on: March 30, 2022
Matrix metalloproteinase inhibitors: a review
1Cancer Studies Unit, Department of Surgery, Queens Medical Centre, University of Nottingham, Nottingham, England.
Summary
Matrix metalloproteinase (MMP) inhibitors show promise for treating cancer by targeting tumor growth and metastasis. Research focuses on synthetic inhibitors and their combination with chemotherapy for enhanced efficacy.
Area of Science:
- Biochemistry
- Oncology
- Pharmacology
Background:
- Matrix metalloproteinases (MMPs) are zinc-dependent enzymes degrading extracellular matrix.
- MMPs are implicated in physiological processes and pathological conditions, including tumor growth and metastasis.
- Naturally occurring tissue inhibitors of MMPs (TIMPs) are not yet therapeutic drugs.
Purpose of the Study:
- To review subgroups of matrix metalloproteinase (MMP) inhibitors.
- To discuss preclinical evaluation and preliminary clinical trial data of MMP inhibitors.
- To explore future developments in MMP inhibitor therapy for malignant diseases.
Main Methods:
- Review of existing literature on MMP inhibitors.
- Analysis of preclinical studies and available clinical trial information.
- Discussion of preclinical model suitability and clinical trial design challenges.
Main Results:
- Focus on low molecular weight synthetic MMP inhibitors.
- Limited but available data from preliminary clinical trials.
- Identification of various MMP inhibitor subgroups.
Conclusions:
- MMP inhibitors hold potential for cancer treatment.
- Further research is needed on preclinical models and clinical trial design.
- Combination therapy with existing chemotherapy may yield synergistic effects.
